» Articles » PMID: 35926460

Medulloblastoma Group 3 and 4 Tumors Comprise a Clinically and Biologically Significant Expression Continuum Reflecting Human Cerebellar Development

Abstract

Medulloblastoma is currently subclassified into distinct DNA methylation subgroups/subtypes with particular clinico-molecular features. Using RNA sequencing (RNA-seq) in large, well-annotated cohorts of medulloblastoma, we show that transcriptionally group 3 and group 4 medulloblastomas exist as intermediates on a bipolar continuum between archetypal group 3 and group 4 entities. Continuum position is prognostic, reflecting a propensity for specific DNA copy-number changes, and specific switches in isoform/enhancer usage and RNA editing. Examining single-cell RNA-seq (scRNA-seq) profiles, we show that intratumoral transcriptional heterogeneity along the continuum is limited in a subtype-dependent manner. By integrating with a human scRNA-seq reference atlas, we show that this continuum is mirrored by an equivalent continuum of transcriptional cell types in early fetal cerebellar development. We identify distinct developmental niches for all four major subgroups and link each to a common developmental antecedent. Our findings show a transcriptional continuum arising from oncogenic disruption of highly specific fetal cerebellar cell types, linked to almost every aspect of group 3/group 4 molecular biology and clinico-pathology.

Citing Articles

Ferroptosis Transcriptional Regulation and Prognostic Impact in Medulloblastoma Subtypes Revealed by RNA-Seq.

Desterke C, Fu Y, Bonifacio-Mundaca J, Monge C, Pineau P, Mata-Garrido J Antioxidants (Basel). 2025; 14(1).

PMID: 39857430 PMC: 11761645. DOI: 10.3390/antiox14010096.


Genomic landscape of medulloblastoma subtypes in an Asian cohort.

Han D, Jin X, Li J Transl Cancer Res. 2025; 13(12):6721-6731.

PMID: 39816537 PMC: 11730696. DOI: 10.21037/tcr-24-1350.


DHODH Inhibition Suppresses and Inhibits the Growth of Medulloblastoma in a Novel In Vivo Zebrafish Model.

Tsea I, Olsen T, Polychronopoulos P, Tummler C, Sykes D, Baryawno N Cancers (Basel). 2025; 16(24.

PMID: 39766063 PMC: 11674817. DOI: 10.3390/cancers16244162.


Single-cell multi-omics analysis identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma.

Veo B, Wang D, DeSisto J, Pierce A, Vibhakar R Res Sq. 2024; .

PMID: 39711559 PMC: 11661367. DOI: 10.21203/rs.3.rs-5522707/v1.


Dissecting the Impact of Genetic Background on Oncogenic Response to Radiation Exposure in the Mouse Model.

Tanno B, Fratini E, Leonardi S, Novelli F, Pisano V, Mancuso M Cells. 2024; 13(22).

PMID: 39594660 PMC: 11593216. DOI: 10.3390/cells13221912.


References
1.
Okugawa Y, Toiyama Y, Shigeyasu K, Yamamoto A, Shigemori T, Yin C . Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer. J Transl Med. 2018; 16(1):366. PMC: 6299520. DOI: 10.1186/s12967-018-1740-z. View

2.
Aryee M, Jaffe A, Corrada-Bravo H, Ladd-Acosta C, Feinberg A, Hansen K . Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014; 30(10):1363-9. PMC: 4016708. DOI: 10.1093/bioinformatics/btu049. View

3.
Northcott P, Jones D, Kool M, Robinson G, Gilbertson R, Cho Y . Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012; 12(12):818-34. PMC: 3889646. DOI: 10.1038/nrc3410. View

4.
Northcott P, Buchhalter I, Morrissy A, Hovestadt V, Weischenfeldt J, Ehrenberger T . The whole-genome landscape of medulloblastoma subtypes. Nature. 2017; 547(7663):311-317. PMC: 5905700. DOI: 10.1038/nature22973. View

5.
Hu X, Chen J, Shi X, Feng F, Lau K, Chen Y . RNA editing of AZIN1 induces the malignant progression of non-small-cell lung cancers. Tumour Biol. 2017; 39(8):1010428317700001. DOI: 10.1177/1010428317700001. View